WBDE(SZ:002082) Zheng Quan Shi Bao Wang·2026-01-09 11:36Core Viewpoint - The announcement by Wanbangde regarding its Alzheimer's disease project being selected for a national major science and technology project highlights the company's commitment to addressing a significant global health challenge and its recognition in the field of innovative drug development [1][2][3] Group 1: Project Details - Wanbangde Pharmaceutical's Alzheimer's disease project has been approved under the National Major Science and Technology Project for Innovative Drug Development, led by the Shanghai Institute of Materia Medica [1] - The project focuses on the industrialization and clinical research of "Shisuanjianjia Controlled-release Tablets," which is a key component of the clinical evaluation and research of new varieties [1][2] Group 2: Market Context - There are nearly 17 million Alzheimer's disease and related dementia patients in China, indicating a significant market need for innovative treatments [2] - Shisuanjianjia injection, a first-line medication for dementia-related memory disorders, has received multiple national awards and patents in various countries, showcasing its established presence in the market [2] Group 3: Clinical Research - The ongoing large-scale, high-quality Phase II/III clinical study of Shisuanjianjia Controlled-release Tablets employs a multi-center, randomized, double-blind design with placebo and positive control groups to comprehensively evaluate efficacy and safety [2] - This study is notable for being the first in China to set dual primary efficacy endpoints and to utilize Aβ-PET imaging to observe changes in amyloid protein deposition [2] Group 4: Company Impact - The inclusion of Shisuanjianjia Controlled-release Tablets in the national major science and technology project reflects the recognition of its potential clinical value and Wanbangde's research capabilities in the field [3] - The successful implementation of this research task is expected to enhance the company's technical level and market competitiveness in the development of drugs for neurological diseases, positively impacting the clinical development and industrialization of its pipeline products [3]